JCR Pharmaceuticals Co., Ltd. (TYO:4552)
Japan · Delayed Price · Currency is JPY 505.00
-12.00 (-2.32%)
Jul 30, 2026, 2:34 PM JST
JCR Pharmaceuticals Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 40,319 | 40,319 | 33,072 | 42,871 | 34,343 | 51,082 |
Revenue Growth | 21.91% | 21.91% | -22.86% | 24.83% | -32.77% | 69.79% |
Gross Profit Gross Profit Growth | 30,185 | 30,185 | 22,170 | 31,251 | 25,457 | 40,621 |
Operating Income Operating Income Growth | 431 | 431 | -6,410 | 7,532 | 4,977 | 19,935 |
Net Income Net Income Growth | 2,178 | 2,178 | -4,460 | 5,507 | 3,772 | 14,507 |
Earnings Per Share EPS Growth | 17.86 | 17.86 | -36.02 | 43.92 | 30.22 | 116.80 |
EPS Growth | - | - | - | 45.33% | -74.13% | 110.34% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 14,007 | 14,007 | 13,196 | 18,756 | 13,278 | 30,977 |
Total Debt Total Debt Growth | 53,892 | 53,892 | 38,105 | 23,300 | 22,800 | 18,100 |
Net Cash (Debt) Net Cash Growth | -39,885 | -39,885 | -24,909 | -4,544 | -9,522 | 12,877 |
Net Cash Growth | - | - | - | - | - | 57.81% |
Net Cash Per Share Net Cash Per Share Growth | -326.90 | -326.90 | -201.16 | -36.24 | -76.27 | 103.67 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -135 | -135 | -5,791 | 9,312 | -5,500 | 9,289 |
Capital Expenditures CapEx Growth | -11,427 | -11,427 | -9,582 | -1,526 | -7,654 | -11,333 |
Free Cash Flow Free Cash Flow Growth | -11,562 | -11,562 | -15,373 | 7,786 | -13,154 | -2,044 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 74.87% | 74.87% | 67.04% | 72.89% | 74.13% | 79.52% |
Operating Margin | 1.07% | 1.07% | -19.38% | 17.57% | 14.49% | 39.02% |
Pretax Margin | 7.99% | 7.99% | -18.09% | 16.89% | 15.76% | 37.98% |
Profit Margin | 5.40% | 5.40% | -13.49% | 12.85% | 10.98% | 28.40% |
FCF Margin | -28.68% | -28.68% | -46.48% | 18.16% | -38.30% | -4.00% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 | 20.000 |
Dividend Per Share Growth | 0% | 0% | 0% | 0% | 0% | 73.91% |
Dividend Yield | 3.86% | 3.52% | 4.27% | 2.49% | 1.54% | 0.97% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 28.95 | 31.81 | - | 19.47 | 46.74 | 19.25 |
Forward PE | 124.70 | 39.18 | 18.68 | 15.47 | 25.97 | 25.23 |
P/FCF Ratio | - | - | - | 13.77 | - | - |
PS Ratio | 1.56 | 1.72 | 1.78 | 2.50 | 5.13 | 5.47 |